MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
* Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued progression as planned * MRX-4 Injection followed by Contezolid Tablets demonstrated favorable safety and efficacy profiles in patients with...
FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections
SHANGHAI, Jan. 1, 2025 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment ofnon-tuberculous myco...
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 inAustralia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycoba...
MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections
FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused byMycobacterium abscessus (Mab),...
MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference
* MicuRx showcased the latest research progress on their pipeline products, MRX-5 and MRX-8, at the 7th World Bronchiectasis Conference * Three significant study results further support the potential of MRX-5 and MRX-8 in treating Nontuberculous Mycobacteria (NTM) lung disease and Pseudomonas...
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
